Stock A278650 HLB BIOSTEP CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials HLB bioStep Co.,Ltd.

Equities

A278650

KR7278650007

Biotechnology & Medical Research

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-05-09 pm EDT 		5-day change 1st Jan Change
3,475 KRW -2.80% Intraday chart for HLB bioStep Co.,Ltd. -2.66% +12.46%
Apr. 25 HLB bioStep Co.,Ltd. announced that it expects to receive KRW 1.438165744 billion in funding from Kangstem Biotech Co., Ltd. CI
Mar. 08 Tranche Update on HLB bioStep Co.,Ltd.'s Equity Buyback Plan announced on December 4, 2023. CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023
Capitalization 1 150,365 191,246 219,226 327,966 242,875
Enterprise Value (EV) 1 141,036 183,843 225,137 322,542 233,135
P/E ratio 33.1 x 23.2 x 22.7 x -108 x -1,445 x
Yield - 0.6% 0.7% - -
Capitalization / Revenue 3.27 x 3.27 x 3.4 x 3.8 x 4.6 x
EV / Revenue 3.06 x 3.14 x 3.5 x 3.74 x 4.41 x
EV / EBITDA 19.3 x 20.2 x 18.7 x 34.3 x 102 x
EV / FCF -100 x 73.7 x -14.1 x 247 x -397 x
FCF Yield -1% 1.36% -7.12% 0.41% -0.25%
Price to Book 3.59 x 3.57 x 3.39 x 4.8 x 2.38 x
Nbr of stocks (in thousands) 65,853 68,574 68,867 70,530 78,600
Reference price 2 2,283 2,789 3,183 4,650 3,090
Announcement Date 3/19/20 3/22/21 3/22/22 3/22/23 3/19/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023
Net sales 1 46,040 58,520 64,403 86,277 52,814
EBITDA 1 7,303 9,095 12,033 9,412 2,290
EBIT 1 5,873 7,040 9,007 5,309 -1,186
Operating Margin 12.76% 12.03% 13.99% 6.15% -2.25%
Earnings before Tax (EBT) 1 5,375 9,471 12,827 -2,345 325.7
Net income 1 4,195 8,302 11,031 -2,995 -164
Net margin 9.11% 14.19% 17.13% -3.47% -0.31%
EPS 2 69.00 120.2 140.1 -43.00 -2.138
Free Cash Flow 1 -1,410 2,495 -16,022 1,307 -586.8
FCF margin -3.06% 4.26% -24.88% 1.51% -1.11%
FCF Conversion (EBITDA) - 27.44% - 13.88% -
FCF Conversion (Net income) - 30.06% - - -
Dividend per Share - 16.67 22.22 - -
Announcement Date 3/19/20 3/22/21 3/22/22 3/22/23 3/19/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023
Net Debt 1 - - 5,911 - -
Net Cash position 1 9,329 7,404 - 5,424 9,740
Leverage (Debt/EBITDA) - - 0.4912 x - -
Free Cash Flow 1 -1,410 2,495 -16,022 1,307 -587
ROE (net income / shareholders' equity) 13.8% 17.3% 19% -4.2% -0.06%
ROA (Net income/ Total Assets) 6.97% 6.48% 6.67% 2.51% -0.43%
Assets 1 60,162 128,066 165,420 -119,519 38,053
Book Value Per Share 2 636.0 782.0 938.0 968.0 1,300
Cash Flow per Share 2 79.00 117.0 89.40 211.0 881.0
Capex 1 5,547 3,947 19,598 4,894 4,002
Capex / Sales 12.05% 6.75% 30.43% 5.67% 7.58%
Announcement Date 3/19/20 3/22/21 3/22/22 3/22/23 3/19/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Bio Diagnostics & Testing

1st Jan change Capi.
HLB BIOSTEP CO.,LTD. Stock HLB bioStep Co.,Ltd.
+12.46% 219M
EXACT SCIENCES CORPORATION Stock Exact Sciences Corporation
-27.67% 9.87B
GUARDANT HEALTH, INC. Stock Guardant Health, Inc.
-17.30% 2.74B
BGI GENOMICS CO., LTD. Stock BGI Genomics Co., Ltd.
-11.15% 2.24B
VERACYTE, INC. Stock Veracyte, Inc.
-22.32% 1.63B
MARAVAI LIFESCIENCES HOLDINGS, INC. Stock Maravai LifeSciences Holdings, Inc.
+59.69% 1.39B
CAREDX, INC Stock CareDx, Inc
+23.58% 772M
SEEGENE, INC. Stock Seegene, Inc.
-1.31% 760M
ADAPTIVE BIOTECHNOLOGIES CORPORATION Stock Adaptive Biotechnologies Corporation
-28.57% 516M
CURIOX BIOSYSTEMS CO., LTD Stock Curiox Biosystems Co., Ltd
+5.37% 310M
Bio Diagnostics & Testing
  1. Stock Market
  2. Equities
  3. A278650 Stock
  4. Financials HLB bioStep Co.,Ltd.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW